Cardiol Therapeutics Inc Class A (CRDL)

Cardiol Therapeutics Inc Class A (CRDL) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $146M; returns 1 day -2.6%, 1 week +1.8%, 1 year -4.3%.

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company specializing in the research and development of anti-inflammatory and anti-fibrotic therapies for cardiovascular diseases. The company's business model is centered on its lead drug candidate, CardiolRx™, a pharmaceutically manufactured, ultra-pure, oral cannabidiol (CBD) formulation that is free of THC.

Groups CRDL belongs to

• Canada Companies
• Biotechnology
• Clinical Stage
• Clinical Stage Biotech
• Healthcare
• Cardiovascular Therapies
• Biopharmaceutical
• Rare Diseases
• Pharmaceuticals
• Cannabis
• Drug Discovery

CRDL financial model: income statement, cash flow and balance sheet